171 related articles for article (PubMed ID: 31118665)
1. Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials.
Casadei Gardini A; Puzzoni M; Montagnani F; Marisi G; Tamburini E; Cucchetti A; Solaini L; Foschi FG; Conti F; Ercolani G; Cascinu S; Scartozzi M
Onco Targets Ther; 2019; 12():2981-2988. PubMed ID: 31118665
[No Abstract] [Full Text] [Related]
2. A Comparison of Lenvatinib versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma: Selection Criteria to Guide Physician's Choice in a New Therapeutic Scenario.
Dipasquale A; Marinello A; Santoro A
J Hepatocell Carcinoma; 2021; 8():241-251. PubMed ID: 33884259
[TBL] [Abstract][Full Text] [Related]
3. Relative Efficacy of Systemic Treatments for Patients with Advanced Hepatocellular Carcinoma According to Viral Status: A Systematic Review and Network Meta-Analysis.
Park J; Cho J; Lim JH; Lee MH; Kim J
Target Oncol; 2019 Aug; 14(4):395-403. PubMed ID: 31290003
[TBL] [Abstract][Full Text] [Related]
4. First-line targ veted therapies of advanced hepatocellular carcinoma: A Bayesian network analysis of randomized controlled trials.
Ding W; Tan Y; Qian Y; Xue W; Wang Y; Jiang P; Xu X
PLoS One; 2020; 15(3):e0229492. PubMed ID: 32134981
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials.
Cucchetti A; Piscaglia F; Pinna AD; Djulbegovic B; Mazzotti F; Bolondi L
Liver Cancer; 2017 Nov; 6(4):337-348. PubMed ID: 29234637
[TBL] [Abstract][Full Text] [Related]
6. Systemic Treatment of Patients with Advanced, Unresectable Hepatocellular Carcinoma: Emergence of Therapies.
Sun W; Cabrera R
J Gastrointest Cancer; 2018 Jun; 49(2):107-115. PubMed ID: 29453759
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib as a therapy for unresectable hepatocellular carcinoma.
Spallanzani A; Orsi G; Andrikou K; Gelsomino F; Rimini M; Riggi L; Cascinu S
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1069-1076. PubMed ID: 30220234
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of lenvatinib treatment for patients with unresectable hepatocellular carcinoma (uHCC) compared with sorafenib in Japan.
Kobayashi M; Kudo M; Izumi N; Kaneko S; Azuma M; Copher R; Meier G; Pan J; Ishii M; Ikeda S
J Gastroenterol; 2019 Jun; 54(6):558-570. PubMed ID: 30788569
[TBL] [Abstract][Full Text] [Related]
9. Lenvatinib versus sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis.
Facciorusso A; Tartaglia N; Villani R; Serviddio G; Ramai D; Mohan BP; Chandan S; Abd El Aziz MA; Evangelista J; Cotsoglou C; Ambrosi A
Am J Transl Res; 2021; 13(4):2379-2387. PubMed ID: 34017396
[TBL] [Abstract][Full Text] [Related]
10. Lenvatinib versus Sorafenib as first-line treatment in hepatocellular carcinoma: A multi-institutional matched case-control study.
Rimini M; Shimose S; Lonardi S; Tada T; Masi G; Iwamoto H; Lai E; Burgio V; Hiraoka A; Ishikawa T; Soldà C; Shirono T; Vivaldi C; Takaguchi K; Shimada N; Astara G; Koga H; Nouso K; Joko K; Torimura T; Hiasa Y; Salani F; Scartozzi M; Cascinu S; Casadei-Gardini A
Hepatol Res; 2021 Dec; 51(12):1229-1241. PubMed ID: 34591334
[TBL] [Abstract][Full Text] [Related]
11. Lenvatinib: a potential breakthrough in advanced hepatocellular carcinoma?
Oikonomopoulos G; Aravind P; Sarker D
Future Oncol; 2016 Feb; 12(4):465-76. PubMed ID: 26785762
[TBL] [Abstract][Full Text] [Related]
12. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib.
Díaz-González Á; Sanduzzi-Zamparelli M; Sapena V; Torres F; LLarch N; Iserte G; Forner A; da Fonseca L; Ríos J; Bruix J; Reig M
Aliment Pharmacol Ther; 2019 Mar; 49(5):482-491. PubMed ID: 30695819
[TBL] [Abstract][Full Text] [Related]
13. Drug-Induced Hypertension Caused by Multikinase Inhibitors (Sorafenib, Sunitinib, Lenvatinib and Axitinib) in Renal Cell Carcinoma Treatment.
Bæk Møller N; Budolfsen C; Grimm D; Krüger M; Infanger M; Wehland M; E Magnusson N
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547602
[TBL] [Abstract][Full Text] [Related]
14. Lenvatinib mesylate to treat hepatocellular carcinoma.
Ielasi L; Tovoli F; Piscaglia F
Drugs Today (Barc); 2019 May; 55(5):305-313. PubMed ID: 31131841
[TBL] [Abstract][Full Text] [Related]
15. Effects of Subsequent Systemic Anticancer Medication Following First-Line Lenvatinib: A Post Hoc Responder Analysis from the Phase 3 REFLECT Study in Unresectable Hepatocellular Carcinoma.
Alsina A; Kudo M; Vogel A; Cheng AL; Tak WY; Ryoo BY; Evans TRJ; López López C; Daniele B; Misir S; Ren M; Izumi N; Qin S; Finn RS
Liver Cancer; 2020 Jan; 9(1):93-104. PubMed ID: 32071913
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib
Kuzuya T; Ishigami M; Ito T; Ishizu Y; Honda T; Ishikawa T; Fujishiro M
Anticancer Res; 2020 Apr; 40(4):2283-2290. PubMed ID: 32234927
[TBL] [Abstract][Full Text] [Related]
17. A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine.
Fleeman N; Houten R; Chaplin M; Beale S; Boland A; Dundar Y; Greenhalgh J; Duarte R; Shenoy A
BMC Cancer; 2019 Dec; 19(1):1209. PubMed ID: 31830943
[TBL] [Abstract][Full Text] [Related]
18. Cost Effectiveness of Lenvatinib, Sorafenib and Placebo in Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer.
Wilson L; Huang W; Chen L; Ting J; Cao V
Thyroid; 2017 Aug; 27(8):1043-1052. PubMed ID: 28486081
[TBL] [Abstract][Full Text] [Related]
19. Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma.
Terashima T; Yamashita T; Takata N; Toyama T; Shimakami T; Takatori H; Arai K; Kawaguchi K; Kitamura K; Yamashita T; Sakai Y; Mizukoshi E; Honda M; Kaneko S
Hepatol Res; 2020 Jul; 50(7):871-884. PubMed ID: 32307874
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.
Cheng AL; Kang YK; Lin DY; Park JW; Kudo M; Qin S; Chung HC; Song X; Xu J; Poggi G; Omata M; Pitman Lowenthal S; Lanzalone S; Yang L; Lechuga MJ; Raymond E
J Clin Oncol; 2013 Nov; 31(32):4067-75. PubMed ID: 24081937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
